Abstract: Programmable RNA-cleaving DNAzymes (RCDs) represent a unique class of catalytic nucleic acids that couple molecular recognition with enzyme-like activity. While DNAzymes have traditionally been explored for targeted gene regulation, recent advances in nanotechnology have repositioned them as programmable biosensing modules with stimuli-responsive therapeutic potential. When integrated into metal-oxide scaffolds, DNA-framework architectures, or metal-organic frameworks, DNAzymes form hybrid platforms that create confined catalytic microenvironments, provide enriched cofactor availability, and facilitate microenvironment-responsive activation. These engineered systems can function as nanoscale biosensing modules that respond to pH, redox gradients, metal ions, or microRNA signatures and convert these biological cues into catalytic outputs. Beyond enhancing analytical performance, such platforms may also reshape tumor immunometabolism. Through the selective cleavage of metabolic or immune-regulatory transcripts, DNAzyme nanocatalysts can directly reprogram glycolysis, redox balance, oxygen tension, and mitochondrial activity, and these metabolic changes in turn alleviate immunosuppression and promote innate and adaptive immune activation. This review outlines the mechanistic foundations of DNAzyme catalysis, summarizes recent nanoengineering strategies that endow DNAzymes with programmable sensing and stimuli-responsive functions, and discusses how these systems bridge biosensing and catalytic immunometabolic functions. We conclude with perspectives on translational challenges and opportunities, endorsing programmable DNAzyme nanocatalysts as emerging preclinical platforms for biosensing-guided immunometabolic intervention.

程序化DNAzyme纳米催化剂调控肿瘤免疫代谢

[1]BinnewiesM, RobertsEW, KerstenK, et al., 2018. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med, 24(5):541-550.

[2]BorggräfeJ, VictorJ, RosenbachH, et al., 2022. Time-resolved structural analysis of an RNA-cleaving DNA catalyst. Nature, 601(7891):144-149.

[3]CaiWQ, LiuJ, ChenXH, et al., 2022. Orthogonal chemical activation of enzyme-inducible CRISPR/Cas9 for cell-selective genome editing. J Am Chem Soc, 144(48):22272-22280.

[4]ChenC, DuSY, LuQL, et al., 2023. Tumor-associated miRNAs activated HCR-DNAzyme theranostic nanosystem to trigger innate- and adaptive-immune responses for long-term immunotherapy. Chem Eng J, 473:145192.

[5]ChenC, DuSY, LuQL, et al., 2025. Spatiotemporally delivery of Cas9 ribonucleoprotein/DNAzyme logic systems using near-infrared upconversion nanomachine for precise immunotherapy. Acta Pharm Sin B, 15(10):5431-5443.

[6]ChenY, GuoY, WangJL, et al., 2024. Engineering self-catabolic DNAzyme nanospheres for synergistic anticancer therapy. Sci China Chem, 67(7):2412-2422.

[7]ChenY, GuoZK, LiJ, et al., 2025. Smart nucleic acid nanodrug delivery system for precision therapeutics. Coord Chem Rev, 535:216673.

[8]CramerER, StarcovicSA, AveyRM, et al., 2023. Structure of a 10-23 deoxyribozyme exhibiting a homodimer conformation. Commun Chem, 6:119.

[9]DongX, XiaS, DuSB, et al., 2023. Tumor metabolism-rewriting nanomedicines for cancer immunotherapy. ACS Cent Sci, 9(10):1864-1893.

[10]DuRR, CedroneE, RomanovA, et al., 2022. Innate immune stimulation using 3D wireframe DNA origami. ACS Nano, 16(12):20340-20352.

[11]DuSY, ChenC, QuSC, et al., 2022. DNAzyme-assisted nano-herb delivery system for multiple tumor immune activation. Small, 18(45):2203942.

[12]DuZ, WuXQ, DangY, et al., 2025. Molecular bioengineering of functional nucleic acids. Nat Rev Bioeng, 4(2):153-170.

[13]FanDH, CaoYK, CaoMQ, et al., 2023. Nanomedicine in cancer therapy. Sig Transduct Target Ther, 8:293.

[14]GuoJ, LiuP, WeiBL, et al., 2023. Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme. Nano Today, 48:101722.

[15]GuoJL, WuLG, LiuCX, et al., 2024. DNAzyme-loaded bimetallic nanoflowers for STING activation and dual metabolic regulation to enhance antitumor immunity. Chem Eng J, 501:157697.

[16]GuoYD, HuP, ShiJL, 2024. Nanomedicine remodels tumor microenvironment for solid tumor immunotherapy. J Am Chem Soc, 146(15):10217-10233.

[17]HuangK, HanY, ChenYH, et al., 2025. Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy. Mol Cancer, 24:7.

[18]JingXD, HuH, SunYZ, et al., 2022. The intracellular and extracellular microenvironment of tumor site: the trigger of stimuli-responsive drug delivery systems. Small Methods, 6(3):2101437.

[19]JouhaJ, XiongH, 2021. DNAzyme‐functionalized nanomaterials: recent preparation, current applications, and future challenges. Small, 17(51):2105439.

[20]KaoKC, VilboisS, TsaiCH, et al., 2022. Metabolic communication in the tumour‒immune microenvironment. Nat Cell Biol, 24(11):1574-1583.

[21]KaymakI, WilliamsKS, CantorJR, et al., 2021. Immunometabolic interplay in the tumor microenvironment. Cancer Cell, 39(1):28-37.

[22]KhanS, BurciuB, FilipeCDM, et al., 2021. DNAzyme-based biosensors: immobilization strategies, applications, and future prospective. ACS Nano, 15(9):13943-13969.

[23]LiF, YuWT, ZhangJJ, et al., 2021. Spatiotemporally programmable cascade hybridization of hairpin DNA in polymeric nanoframework for precise siRNA delivery. Nat Commun, 12:1138.

[24]LiF, SongNC, DongYH, et al., 2022. A proton-activatable DNA-based nanosystem enables co-delivery of CRISPR/Cas9 and DNAzyme for combined gene therapy. Angew Chem Int Ed, 61(9):e202116569.

[25]LiXY, GaoJJ, WuCC, et al., 2024. Precise modulation and use of reactive oxygen species for immunotherapy. Sci Adv, 10(20):eadl0479.

[26]LiYL, ZhaoPR, GongT, et al., 2020. Redox dyshomeostasis strategy for hypoxic tumor therapy based on DNAzyme‐loaded electrophilic ZIFs. Angew Chem Int Ed, 59(50):22537-22543.

[27]LiuCZ, ChenYX, ZhaoJ, et al., 2021. Self-assembly of copper-DNAzyme nanohybrids for dual-catalytic tumor therapy. Angew Chem Int Ed, 60(26):14324-14328.

[28]LiuHH, YuX, ChenYQ, et al., 2017. Crystal structure of an RNA-cleaving DNAzyme. Nat Commun, 8:2006.

[29]LiuP, ShiXY, PengY, et al., 2022. Anti-PD-L1 DNAzyme loaded photothermal Mn²⁺/Fe³⁺ hybrid metal-phenolic networks for cyclically amplified tumor ferroptosis-immunotherapy. Adv Healthcare Mater, 11(8):2102315.

[30]LiuSW, LiuZJ, LeiHJ, et al., 2025. Programmable nanomodulators for precision therapy, engineering tumor metabolism to enhance therapeutic efficacy. Adv Healthcare Mater, 14(4):2403019.

[31]LiuYF, ZhuP, HuangJ, et al., 2022. Integrating DNA nanostructures with DNAzymes for biosensing, bioimaging and cancer therapy. Coord Chem Rev, 468:214651.

[32]MengLX, MaWJ, LinSY, et al., 2019. Tetrahedral DNA nanostructure-delivered DNAzyme for gene silencing to suppress cell growth. ACS Appl Mater Interfaces, 11(7):6850-6857.

[33]MuS, YangHY, WangSQ, et al., 2025. Zinc-based nanomaterials in cancer therapy: mechanisms, applications, and future directions. Theranostics, 15(15):7841-7871.

[34]Muñoz-GonzálezM, Silva-GalleguillosV, Parra-MenesesV, et al., 2025. Catalytic mechanisms of the 8-17 and 10-23 DNAzymes: shared mechanistic strategies. Org Biomol Chem, 23(19):4564-4577.

[35]NguyenK, MalikTN, ChaputJC, 2023. Chemical evolution of an autonomous DNAzyme with allele-specific gene silencing activity. Nat Commun, 14:2413.

[36]NorianLA, RodriguezPC, O'MaraLA, et al., 2009. Tumor-infiltrating regulatory dendritic cells inhibit CD8⁺ T cell function via L-arginine metabolism. Cancer Res, 69(7):3086-3094.

[37]RennickJJ, JohnstonAPR, PartonRG, 2021. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat Nanotechnol, 16(3):266-276.

[38]RosenbachH, VictorJ, EtzkornM, et al., 2020. Molecular features and metal ions that influence 10-23 DNAzyme activity. Molecules, 25(13):3100.

[39]SantoroSW, JoyceGF, 1998. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry, 37(38):13330-13342.

[40]ScharpingNE, RivadeneiraDB, MenkAV, et al., 2021. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol, 22(2):205-215.

[41]ShiXX, MengHM, GengX, et al., 2020. DNAzyme‒metal‒organic framework two-photon nanoprobe for in situ monitoring of apoptosis-associated Zn²⁺ in living cells and tissues. ACS Sens, 5(10):3150-3157.

[42]SuJX, SunCY, DuJY, et al., 2023. RNA-cleaving DNAzyme-based amplification strategies for biosensing and therapy. Adv Healthcare Mater, 12(23):2300367.

[43]SuRR, ShaoYY, HuangMR, et al., 2024. Immunometabolism in cancer: basic mechanisms and new targeting strategy. Cell Death Discov, 10:236.

[44]TanYY, LiJJ, ZhaoGY, et al., 2022. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun, 13:4554.

[45]WangF, LiuZC, LiuYC, et al., 2024. A spatiotemporally controlled gene-regulation strategy for combined tumor therapy based on upconversion hybrid nanosystem. Adv Sci, 11(40):2405640.

[46]WangHM, ChenYQ, WangH, et al., 2019. DNAzyme-loaded metal‒organic frameworks (MOFs) for self-sufficient gene therapy. Angew Chem Int Ed, 58(22):7380-7384.

[47]WangJ, WangHM, WangH, et al., 2019. Nonviolent self-catabolic DNAzyme nanosponges for smart anticancer drug delivery. ACS Nano, 13(5):5852-5863.

[48]WangJ, LiYY, NieGJ, 2021. Multifunctional biomolecule nanostructures for cancer therapy. Nat Rev Mater, 6(9):766-783.

[49]WangL, TangSQ, LiL, et al., 2023. Nucleic acids enabled-interfacial engineering for biomarker sensing with distance constraint effects. Adv Sensor Res, 2(4):2200062.

[50]WangR, HeWH, YiX, et al., 2023. Site-specific bioorthogonal activation of DNAzymes for on-demand gene therapy. J Am Chem Soc, 145(32):17926-17935.

[51]WangYJ, NguyenK, SpitaleRC, et al., 2021. A biologically stable DNAzyme that efficiently silences gene expression in cells. Nat Chem, 13(4):319-326.

[52]WangZ, NiuJS, ZhaoCQ, et al., 2021. A bimetallic metal‒organic framework encapsulated with DNAzyme for intracellular drug synthesis and self-sufficient gene therapy. Angew Chem Int Ed, 60(22):12431-12437.

[53]WangZ, YangJ, QinG, et al., 2022. An intelligent nanomachine guided by DNAzyme logic system for precise chemodynamic therapy. Angew Chem Int Ed, 61(38):e202204291.

[54]WieruszewskaJ, PawłowiczA, PołomskaE, et al., 2024. The 8-17 DNAzyme can operate in a single active structure regardless of metal ion cofactor. Nat Commun, 15:4218.

[55]WuSX, ZhangKX, LiangY, et al., 2022. Nano-enabled tumor systematic energy exhaustion via zinc(II) interference mediated glycolysis inhibition and specific GLUT1 depletion. Adv Sci, 9(7):2103534.

[56]XuMJ, XuC, QiuY, et al., 2024. Zinc-based radioenhancers to activate tumor radioimmunotherapy by PD-L1 and cGAS-STING pathway. J Nanobiotechnol, 22:782.

[57]YanJQ, RanMX, ShenX, et al., 2023. Therapeutic DNAzymes: from structure design to clinical applications. Adv Mater, 35(30):2300374.

[58]YanJQ, BhadaneR, RanMX, et al., 2024. Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy. Nat Commun, 15:3684.

[59]YuLY, YangS, LiuZY, et al., 2022. Programming a DNA tetrahedral nanomachine as an integrative tool for intracellular microRNA biosensing and stimulus-unlocked target regulation. Mater Today Bio, 15:100276.

[60]YuanHM, JiaoZC, WangT, et al., 2025. Endogenously activated multiple DNAzyme-encoded nanoflowers for high-contrast imaging of long noncoding RNA and cancer therapy. ACS Nano, 19(41):36397-36410.

[61]ZhangHB, ZhuQB, 2026. Recent advances in DNAzyme systems for disease diagnosis and therapy. Adv Healthcare Mater, 15(6):e04385.

[62]ZhangLX, DiaoQJ, LiB, et al., 2025. Delivery system of nanozymes loaded with DNAzymes and hypoxia-activated prodrug for anti-tumor metastasis. Small, 21(36):2504778.

[63]ZhangP, OuyangY, SohnYS, et al., 2021. pH- and miRNA-responsive DNA-tetrahedra/metal‒organic framework conjugates: functional sense-and-treat carriers. ACS Nano, 15(4):6645-6657.

[64]ZhaoS, WangXS, DengRJ, et al., 2025. A trinity DNAzyme circuit with dual-confinement effect for imaging-guided combined gene/chemo-dynamic therapy. Adv Funct Mater, 35(23):2422309.

[65]ZhaoX, WangYY, JiangWX, et al., 2022. Herpesvirus-mimicking DNAzyme-loaded nanoparticles as a mitochondrial DNA stress inducer to activate innate immunity for tumor therapy. Adv Mater, 34(37):2204585.

[66]ZhaoX, ChengH, WangQW, et al., 2023. Regulating photosensitizer metabolism with DNAzyme-loaded nanoparticles for amplified mitochondria-targeting photodynamic immunotherapy. ACS Nano, 17(14):13746-13759.

[67]ZhaoY, YeZF, SongDH, et al., 2023. Nanomechanical action opens endo-lysosomal compartments. Nat Commun, 14:6645.

[68]ZhaoZH, ZhouJY, LiXW, et al., 2025. Manganese-based virus-mimicking nanomedicine with triple immunomodulatory functions inhibits breast cancer brain metastasis. Biomaterials, 320:123262.

[69]ZhengX, MundA, MannM, 2025. Deciphering functional tumor-immune crosstalk through highly multiplexed imaging and deep visual proteomics. Mol Cell, 85(5):1008-1023.e7.

[70]ZhuXG, XuJQ, LingGX, et al., 2023. Tunable metal‒organic frameworks assist in catalyzing DNAzymes with amplification platforms for biomedical applications. Chem Soc Rev, 52(21):7549-7578.

Similar articles